|Articles|April 15, 2003
- BioPharm International-04-01-2003
- Volume 16
- Issue 4
Guest Editorial: Benchmarking Biotech
Author(s)Michael E. Kamarck
by Michael Kamarck, Wyeth BioPharma
Advertisement
Articles in this issue
almost 23 years ago
Virus Inactivation in the 1990s and into the 21st Centuryalmost 23 years ago
Getting Ready for Risk-Based GMPsalmost 23 years ago
GMP Issues: Breaking Groundalmost 23 years ago
Optimized Nutrient Additives for Fed-Batch Culturesalmost 23 years ago
Inside Washington: GMP Progress ReportNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
3
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
4
High-Dose Nusinersen Slows Neurodegeneration in SMA Patients, Study Shows
5
